

## Susan L. Rosenkranz, PhD

*CURRICULUM VITAE, JUNE 2018*

Frontier Science                      617 632 2000, extension 5915  
1371 Beacon Street, Suite 203              srosenkr@sdac.harvard.edu  
Brookline, MA 02446

### **EDUCATION**

- 1994              Pew Health Policy Postdoctoral Fellowship  
University of California, San Francisco
- 1992              PhD, Biostatistics  
University of Washington, Seattle WA
- 1991              MS, Biostatistics  
University of Washington, Seattle WA
- 1980              BS, Cellular and Molecular Biology, *Cum Laude*  
University of Washington, Seattle WA

### **PROFESSIONAL EXPERIENCE**

- 2017-present    Director of Biostatistics, Boston Office  
Frontier Science (Frontier Science and Technology  
Research Foundation, Inc.)  
Brookline MA
- 2006-present    Visiting Scientist  
Center for Biostatistics in AIDS Research  
Harvard TH Chan School of Public Health  
Boston MA
- 2002-2017       Senior Research Scientist  
Frontier Science  
Brookline MA
- 1999-2002       Senior Biostatistician  
Center for Biostatistics in AIDS Research  
Harvard School of Public Health  
Boston MA
- 1994 to 1998    Senior Biostatistician  
Deputy Medical Director's Office  
Harvard Pilgrim Health Care

Brookline MA

- 1992 to 1994 Postdoctoral Fellow, Pew Health Policy Program  
Institute for Health Policy Studies  
University of California, San Francisco CA
- 1990 to 1991 Teaching Assistant, Department of Health Services  
University of Washington, Seattle WA
- 1990 to 1991 Lecturer  
Children's Hospital and Medical Center, Seattle WA
- 1988 to 1989 Research Technologist, Department of Psychology  
University of Washington, Seattle WA
- 1981 to 1988 Systems Analyst/Programmer, Regional Primate  
Research Center, University of Washington, Seattle WA

**COMPUTING LANGUAGES AND ENVIRONMENTS**

*Statistical and programming:* SAS, Splus, R, SPSS, FORTRAN.

*Environments:* Windows, Linux, UNIX.

*Other:* Latex, Microsoft.

**PROFESSIONAL AND COMMUNITY SERVICE**

**Reviewer**

2014, NIDA-ACTG Pharmacology-Related RFPs

**Consultant Reviewer**

2016, *Drug Safety*

2012, *British Journal of Clinical Pharmacology*

2007, Statistical and Data Coordinating Center applications, Clinical Research in  
Infectious Diseases, NIAID, NIH

2006-2008, *Journal of the American Medical Association*

2002-2003, *Clinical and Diagnostic Laboratory Immunology*

1996-2000, *Journal of Bone and Joint Surgery*

1994-1996, *American Journal of Sociology, Australian Journal of Statistics, Journal of  
the American Statistical Association, Sociological Methodology*, and for The Zitter  
Group.

**Member and Statistician Representative**, Tuberculosis Transformative Science Group,  
ACTG, 2011-present

**Member and Statistician Representative**, Pharmacology Committee, ACTG, 1999-2005

**Member and Statistician**, Adherence, Exposure and Response Working Group, ACTG,  
1999-2005

**Council of Sections Representative**, Health Policy Statistics Section of the American Statistical Association, 1996-1998.

**Fellows Representative**, Institute for Health Policy Studies, University of California, San Francisco, November 1992-1993.

**Creator and lead volunteer of the Cooking Nights program**, Reservoir Church at the Fresh Pond Apartments, Cambridge MA. 2013-present.

**Homework Club Tutor**, Vineyard Community Offerings at Fresh Pond Apartments, Cambridge MA. 2012-2016.

**Art Volunteer**, Richmond District Neighborhood Center, 1993-1994.

### **HONORS**

National Research Service Award/United States Public Health Service Trainee, National Cancer Institute, Cancer Epidemiology and Biostatistics Training Grant, January 1990 to August 1992.

Graduate School Tuition scholarship for Outstanding Academic Achievement, Spring 1988.

### **PUBLICATIONS IN PEER-REVIEWED JOURNALS**

Kiser JJ, Lu D, **Rosenkranz SL**, Morse GD, DiFrancesco R, Sherman KE, Butt AA, ACTG A5309s study team. Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s. *Drugs R&D*. 2017 Dec;17(4):557-567. PMID: 28875397, PMCID: PMC5694418, DOI: 10.1007/s40268-017-0205-9.

Martirosov DM, Bidell M, Pai MP, Scheetz MH, **Rosenkranz SL** and Lodise TP. Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin MICE<sub>TEST</sub> values of 1.5 mg/L: A pilot study. *Diagnostic Microbiology and Infectious Disease*. 2017 Apr 2.

Huvane J, Komarow L, Hill C, Tran TT, Pereira C, **Rosenkranz SL**, Finnemeyer M, Earley M, Jiang HJ, Wang R, Lok J, Evans SR; Statistical and Data Management Center of the Antibacterial Resistance Leadership Group (ARLG). Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. *Clin Infect Dis*. 2017 Mar 15;64(suppl\_1):S18-S23. doi: 10.1093/cid/ciw827. PMID: 28350899 [PubMed - in process]

De Boni RB, Zheng L, **Rosenkranz SL**, Sun X, Lavenberg J, Cardoso SW, Grinsztejn B, La Rosa A, Pierre S, Severe P, Cohn SE, Collier AC, Gross R. Binge Drinking is Associated with Differences in Weekday and Weekend Adherence in HIV-Infected Individuals. *Drug and Alcohol Dependence* 2016; 159:174-180. PMID: 26774947 [PubMed - in process]

Andrade A, Guedj J, **Rosenkranz SL**, Lu D, Mellors J, Kuritzkes DR, Perelson AS, Ribeiro RM for the ACTG A5249s protocol team. Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). *AIDS* 2015 Nov;29(18):2419-2426. doi: 10.1097/QAD.0000000000000843. NIHMS 715501. Pubmed PMID 26558541; PubMed Central PMCID: PMC4646723.

Luetkemeyer AF, **Rosenkranz SL**, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV and Haas DW. Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure during Rifampin-based Anti-Tuberculosis Therapy in the STRIDE Study. [ACTG A5221, A5243, NWCS 364.] *Clin Infect Dis*. 2015 Jun 15;60(12):1860-3. doi: 10.1093/cid/civ155. Epub 2015 Feb 26. PubMed PMID: 25722197. PubMed Central PMCID: PMC4542662.

Gross R, Zheng L, La Rosa A, Sun X, **Rosenkranz SL**, Wagner Cardoso S, Ssali F, Camp R, Godfrey C, Cohn SE, Robbins GK, Chisada A, Wallis CL, Reynolds NR, Lu D, Safren SA, Hosey L, Severe P, Collier AC. Partner-Focused Adherence Intervention for Second-line Antiretroviral Therapy: A Multinational Randomized Trial (ACTG A5234). *Lancet HIV*. 2015 Jan 1;2(1):e12-e19. PubMed PMID: 25664336; PubMed Central PMCID: PMC4313760.

DiFrancesco R, Taylor CR, **Rosenkranz SL**, Tooley KM, Pande PG, Siminski SM, Jenny RW and Morse GD. Adding value to antiretroviral proficiency testing. *Bioanalysis*. 2014 Oct;6(20):2721-32. doi: 10.4155/bio.14.139. PubMed PMID: 25413704; PubMed Central PMCID: PMC4296581.

Funderburg NT, Andrade A, Chan ES, **Rosenkranz SL**, Lu D, Clagett B, Pilch-Cooper HA, Rodriguez B, Feinberg J, Daar E, Mellors J, Kuritzkes D, Jacobson JM, Lederman MM. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. *PLoS One*. 2013 Dec 18;8(12):e83514. doi: 10.1371/journal.pone.0083514. eCollection 2013. PubMed PMID: 24367599; PubMed Central PMCID: PMC3867440.

DiFrancesco R, **Rosenkranz SL**, Taylor CR, Pande PG, Siminski SM, Jenny RW and Morse GD. Clinical Pharmacology Quality Assurance Program: Models for Longitudinal Analysis of Antiretroviral Proficiency Testing for International Laboratories. *Ther Drug Monit*. 2013 Oct;35(5):631-42. doi: 10.1097/FTD.0b013e31828f5088. PubMed PMID: 24052065; PubMed Central PMCID: PMC3781596.

Andrade A, **Rosenkranz SL**, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW and Kuritzkes D and for the ACTG 5248 Team. Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naïve Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248 Study. *J Infect Dis*. 2013 Sep;208(6):884-91. doi: 10.1093/infdis/jit272. Epub 2013 Jun 24. PubMed PMID: 23801609; PubMed Central PMCID: PMC3749011.

Luetkemeyer AF, **Rosenkranz SL**, Lu D, Marzan, F, Ive P, Hoff, E, Benson CA, Grinzstejn B, Sanne IM, Havlir DV, Aweeka F. Relationship between weight, efavirenz exposure and virologic suppression in HIV-infected patients on rifampin-based TB treatment in the ACTG A5221 STRIDE study. *Clin Infect Dis*. 2013 Aug;57(4):586-93. doi: 10.1093/cid/cit246. Epub 2013 Apr 16. PubMed PMID: 23592830; PubMed Central PMCID: PMC3719885.

DiFrancesco R, Tooley K, **Rosenkranz SL**, Siminski S, Taylor CR, Pande P, Morse GD. Clinical Pharmacology Quality Assurance for HIV and Related Infectious Diseases Research. *Clin Pharmacol Ther*. Jun 2013; 93(6): 479–482. Published online Mar 26, 2013. doi:10.1038/clpt.2013.62. PMCID: PMC3970711. NIHMSID: NIHMS550941.

Zheng L, **Rosenkranz SL**, Taiwo B, Para MF, Eron, JJ, and Hughes MD. The Design of Single-Arm Clinical Trials of Combination Antiretroviral Regimens for Treatment-Naïve HIV-Infected Patients. *AIDS Res Hum Retroviruses*. 2013 Apr;29(4):652-7. doi: 10.1089/AID.2012.0180. Epub 2013 Jan 9. PubMed PMID: 23228206; PubMed Central PMCID: PMC3607972.

DiFrancesco R, **Rosenkranz SL**, Mukherjee L, Demeter L, Jiang H, DeCenzo R, Dykes C, Rinehart A, Albrecht M and Morse G. Quality Assessment for Therapeutic Drug Monitoring in AIDS Clinical Trials Group (ACTG 5146): A Multicenter Clinical Trial. *Therapeutic Drug Monitoring* 2010; 32(4):458-466. doi: 10.1097/FTD.0b013e3181e4427a. PMC2936454, NIHMS213452.

Cramer YS, **Rosenkranz SL**, Hall SD, Szczech LA, Amorosa V, Gupta SK. Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1 infected persons requiring hemodialysis: Results from ACTG A5177. *J Acquir Immune Defic Syndr*. 2010 Aug;54(4):e7-9. doi: 10.1097/QAI.0b013e3181e2d5e5. PubMed PMID: 20611034; PubMed Central PMCID: PMC2912759.

Asmuth DM, Murphy RL, **Rosenkranz SL**, Lertora JL, Kottlilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li X-D, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB for the ACTG A5192 Team. Safety, Tolerability and Mechanisms of Antiretroviral Activity of Peginterferon alfa-2a in HIV-1-Mono-infected Subjects: A Phase II Clinical Trial. *J Infect Dis*. 2010 Jun 1;201(11):1686-96. doi: 10.1086/652420. PubMed PMID: 20420510; PubMed Central PMCID: PMC2946345.

Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eschleman SH, Aberg J, Sanne I, Parsons T, Kashuba A, **Rosenkranz SL**, Ferguson E, Dehlinger M, Mildvan D, and the ACTG A5073 Study Team. Randomized Prospective Comparison of Once Daily Versus Twice Daily Combination Antiretroviral Therapy: Results of AIDS Clinical Trials Group (ACTG) 5073, A 48-Week Trial. *Clin Infect Dis*. 2010 Apr 1;50(7):1041-52. doi: 10.1086/651118. PubMed PMID: 20192725; PubMed Central PMCID: PMC2833234.

Para M, Schouten J, **Rosenkranz S**, Yu S, Weiner D, Tebas P, White C, Reeds D, Lertora J, Patterson K, Daar E, Cavert W, Brizz B. Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects. ACTG 5200. *J Acquir Immune Defic Syndr*. 2010 Apr 1;53(4):491-5. doi: 10.1097/QAI.0b013e3181d142cb. PubMed PMID: 20130470; PubMed Central PMCID: PMC3477637.

Gross R, Tierney C, Andrade A, Lalama C, **Rosenkranz S**, Eshleman S, Flanigan T, Santana J, Salomon N, Reisler R, Wiggins I, Hogg E, Flexner C and Mildvan D. Modified Directly Observed Antiretroviral Therapy Compared with Self-administered Therapy in Treatment-Naïve HIV-1-Infected Patients: A Randomized Trial. *Archives of Internal Medicine* 2009; 169(13):1224-1232. (ACTG A5073) PMC2771688, NIHMS168892.

Gupta SK, **Rosenkranz SL**, Cramer S, Koletar SL, Szczech LA, Amorosa V and Hall SD. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. *AIDS*. 2008 Oct 1;22(15):1919-27. doi: 10.1097/QAD.0b013e32830e011f. PubMed PMID: 18784455; PubMed Central PMCID: PMC2675161.

Bakshi RP, Hamzeh F, Frank I, Eron JJ, Bosch RJ, **Rosenkranz SL**, Cramer YS, Ussery M, and Flexner C. Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. *AIDS Res Hum Retroviruses*. 2007 Nov;23(11):1360-5. doi: 10.1089/aid.2007.0078. PubMed PMID: 18184078.

Ma Q, Forrest A, **Rosenkranz SL**, Para MF, Yarasheski KE, Reichman RC, Morse GD; ACTG A5043 Protocol Team, DAIDS, NIH. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers *Biopharm Drug Dispos*. 2008 Mar;29(2):91-101. PubMed PMID: 18041735; PubMed Central PMCID: PMC4307806.

**Rosenkranz SL**, Yarasheski KE, Para MF, Reichman RC, Morse GD. Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis. *Metab Syndr Relat Disord*. 2007 Jun;5(2):163-73. PubMed PMID: 18007962; PubMed Central PMCID: PMC2078603.

DiFrancesco R, **Rosenkranz SL**, Craft J and Morse GD. Tutorial reduces protocol deviations in multicenter ACTG trials with pharmacology endpoints. *HIV Clin Trials*. 2006 Jul-Aug;7(4):203-9. PubMed PMID: 17065032.

Aweeka F, **Rosenkranz SL**, Segal Y, Coombs R, Bardeguez A, Thevanayagam L, Lizak P, Aberg J, Watts DH and the NIAID AIDS Clinical Trials Group. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine:

AIDS Clinical Trials Group 317. AIDS. 2006 Sep 11;20(14):1833-41. PubMed PMID: 16954724.

Wu H, Huang Y, Acosta EP, Park J-G, Yu S, **Rosenkranz SL**, Kuritzkes DR, Eron JJ, Perelson AS and Gerber JG. Pharmacodynamics of antiretroviral agents in HIV-1 infected patients using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn. 2006 Aug;33(4):399-419. Epub 2006 Apr 1. PubMed PMID: 16583266.

Aberg JA, **Rosenkranz SL**, Fichtenbaum CJ, Alston B, Brobst S, Segal Y and Gerber JG for the ACTG A5108 Team. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV seronegative volunteers: ACTG study A5108. AIDS. 2006 Mar 21;20(5):725-9. PubMed PMID: 16514303; PubMed Central PMCID: PMC1459289.

Gerber JG, **Rosenkranz SL**, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y and Aberg JA for the ACTG A5108 Team. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of ACTG 5108 Study. J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):307-12. PubMed PMID: 15980690.

Wu H, Huang Y, Acosta EP, **Rosenkranz SL**, Kuritzkes DR, Eron JJ, Perelson, AS and Gerber JG. Modeling long-term HIV dynamics and antiretroviral response: Effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):272-83. PubMed PMID: 15980686.

Huang Y, **Rosenkranz SL** and Wu H. Modeling HIV dynamics and antiviral response as with consideration of time-varying drug exposure, adherence and phenotypic sensitivity. Math Biosci. 2003 Aug;184(2):165-86. PubMed PMID: 12832146.

Washington C, Flexner C, Sheiner LB, **Rosenkranz SL**, Segal Y, Aberg JA, Blaschke TF and the AIDS Clinical Trials Group Protocol 378 (ACTG 378) Study Team. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin Pharmacol Ther. 2003 May;73(5):406-16. PubMed PMID: 12732841.

Perlman DC, Segal Y, **Rosenkranz S**, Rainey PM, Remmel RP, Salomon N, Hafner R and Peloquin CA for the ACTG 309 Team. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. *Clinical Infectious Diseases* 2005; 41:1638-47. PMID 16267738.

Ma Q, Forrest A, **Rosenkranz S**, Para MF, Adams E, Yarasheski KE, Reichman RC, Morse GD. Optimal multi-drug PK sampling strategies (OSS) for efavirenz (EFV) & indinavir (IDV) *Clinical Pharmacology and Therapeutics* 2005; 77:P42-P42. doi: 10.1016/j.clpt.2004.12.052.

Zack YZ, Forrest A, Ma Q, **Rosenkranz S**, Para MF, Adams E, Reichman RC, Yaresheski K, Morse GD. Optimal sparse pharmacokinetic (PK) sampling strategies (OSS) for multi-drug antiretroviral (ARV) regimens. *Clinical Pharmacology and Therapeutics* 2005; 77 P90-P90. doi: 10.1016/j.clpt.2004.12.236.

Morse GD, **Rosenkranz S**, Para MF, Segal Y, DiFrancesco R, Adams E, Brizz B, Yarasheski KE, Reichman RC and the ACTG 5043 Protocol Team. Amprenavir and Efavirenz Pharmacokinetics Before and After the Addition of Nelfinavir, Indinavir, Ritonavir or Saquinavir. *Antimicrobial Agents and Chemotherapy* 2005; 49(8):3373-3381. PMC1196277.

Perlman DC, Segal Y, **Rosenkranz S**, Rainey PM, Peloquin CA, Remmel RP, Chirgwin K, Salomon N and Hafner R, for the ACTG 309 Team. The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. *Clinical Infectious Diseases* 2004; 38:556-564. PMID 14765350.

Pfister M, Labbé L, Hammer SM, Mellors J, Bennett KK, **Rosenkranz SL**, Sheiner LB and the AIDS Clinical Trial Group Protocol 398 Investigators. Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trials Group Study 398. *Antimicrobial Agents and Chemotherapy* 2003; 47(1):130-7. PMC148981.

Lu JF, Blaschke TF, Flexner C, **Rosenkranz SL**, Sheiner LB and AIDS Clinical Trials Group Protocol 378 Investigators. Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir and saquinavir after simultaneous and staggered oral administration. *Drug Metab Dispos.* 2002 Dec;30(12):1455-61. PubMed PMID: 12433819.

Pfister M, Lu J-F, Labbé L, Hammer SM, Mellors J, Bennett KK, **Rosenkranz SL**, Sheiner LB and the AIDS Clinical Trial Group Protocol 398 Investigators. Effect of co-administration of nelfinavir, indinavir and saquinavir on the pharmacokinetics of amprenavir. *Clinical Pharmacology and Therapeutics* 2002; 72(2):133-41. PMID 12189360.

Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg J, Blaschke T, Alston B, Fang F, Kosel B and Aweeka F. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. *AIDS.* 2002 Mar 8;16(4):569-77. PubMed PMID: 11873000.

Gerber JG, **Rosenkranz S**, Segal Y, Aberg J, D'Amico R, Mildvan D, Gulick R, Hughes V, Flexner C, Aweeka F, Hsu A for the ACTG 401 Study Team. The effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: Results of ACTG 401. *Journal of Acquired Immune Deficiency Syndromes* 2001; 27(2):153-60. PMID 11404537.



Krupat E, **Rosenkranz SL**, Yeager CM, Barnard K, Putnam S, and Inui TS. Studying the practice orientations of physicians and patients: The effect of doctor-patient congruence on satisfaction. *Patient Education and Counseling* 2000; 39:49-59.

Dresser MVB, Feingold L, **Rosenkranz SL** and Coltin KL. Clinical quality measurement: Comparing chart review and automated methodologies. *Medical Care* 1997; 35(6):539-52.

**Rosenkranz SL** and Luft HS. Expenditure models for prospective risk adjustment: choosing the measure appropriate for the problem. *Medical Care Research and Review* 1997; 54(2):123-43.

Diehr P, Cain K, Kreuter W, **Rosenkranz S**. Can Small Area Analysis detect variation in surgical rates?: the power of Small Area Variations Analysis. *Medical Care* 1992; 30(6):484-502.

Sarason IG, Sarason BR, Pierce GR, Sayers MH, **Rosenkranz SL**. Promotion of High School Blood Donations: Testing the Efficacy of a Videotaped Intervention. *Transfusion* 1992; 32(9):818-23.

Slattum MM, **Rosenkranz SL**, DiGiacomo RF, Tsai C-C, Giddens WE Jr. Amyloidosis in Pigtailed Macaques (*Macaca nemestrina*): Epidemiologic aspects. *Laboratory Animal Science* 1989; 39:560-566.

Russell RG, **Rosenkranz SL**, Lee LA, Howard H, DiGiacomo RF, Bronsdon MA, Blakley GA, Tsai C-C, Morton WR. Epidemiology and etiology of diarrhea in colony--born *Macaca nemestrina*. *Laboratory Animal Science* 1987; 37:309-16.

Tsai C-C, Giddens WE Jr., Morton WR, **Rosenkranz SL**, Ochs HE, Benveniste RE. Retroperitoneal fibromatosis and acquired immunodeficiency syndrome in Macaques: Epidemiologic studies. *Laboratory Animal Science* 1985; 35:460-4.

Morton WR, Bronsdon M, Mickelsen G, Knitter G, **Rosenkranz S**, Kuller L, Sajuthi D. Identification of *Campylobacter jejuni* in *Macaca fascicularis* imported from Indonesia. *Laboratory Animal Science* 1983; 33:187-8.

***SUBMITTED TO PEER-REVIEWED JOURNALS***

Wenzler E, Bleasdale S, Sikka M, Bunnell K, Finnemeyer M, **Rosenkranz S**, Danziger L, Rodvold K, and the Antibacterial Resistance Leadership Group. Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants (PROOF). Accepted (with revisions) April 22, 2018 by *Antimicrobial Agents and Chemotherapy*.

#### ***MANUSCRIPTS IN PREPARATION***

Lodise TP, **Rosenkranz SL**, Finnemeyer M, Evans S, Huvane J, Pereira C, PROVIDE Site PIs, Fowler VG, Chambers H and Holland TL. Vancomycin Dosing for Methicillin-Resistant *Staphylococcus aureus* Bacteremia.

Johnson VA, **Rosenkranz SL**, Cramer YS, Becker S, Klingman KL, Kallungal B, Zadzilka A, Coakley E, Acosta EP, Calandra G and Saag MS for the NIH/NIAID AIDS Clinical Trials Group A5210 Protocol Team. Proof-of-concept of antiretroviral activity of AMD11070 (an orally administered CXCR4 entry inhibitor): Results of the first dosing cohort studied in NIH/NIAID AIDS Clinical Trials Group (ACTG) protocol A5210.

Martirosov D, Bidell M, Pai M, Scheetz M, **Rosenkranz S**, Faragon C, Malik M, Mendes R, Jones R, McNutt L-A, and Lodise T. Relationship Between Day 1 and Day 2 Vancomycin Area Under the Curve Values and Emergence of Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA) by Etest® Macromethod among Patients with MRSA Bloodstream Infections: A Pilot Study". Submitted May 3, 2016 to *Antimicrobial Agents and Chemotherapy*.

#### ***TECHNICAL REPORTS***

**Rosenkranz SL** and Raftery AE. Covariate selection in hierarchical models of hospital admission counts: a Bayes factor approach. Technical Report 268, Department of Statistics (GN-22), University of Washington, Seattle, WA 98195, April 1994.

Annual Report of the California Hospital Outcomes Project. Office of Statewide Health Planning and Development, State of California. (December 1993)

**Rosenkranz SL** and Raftery AE. Approximate Bayes factors for covariate selection and outlier identification using Gibbs sampling and Laplace approximation. Proceedings of the International Biometric Conference, August 1994.

**Rosenkranz SL**. The Bayes factor for model evaluation in a hierarchical Poisson model for area counts. Unpublished doctoral dissertation, University of Washington, Seattle, WA 98195, July 1992.

#### ***CONFERENCE ABSTRACTS ACCEPTED***

Scarsi KK, Cramer YS, Campbell K, Cirrincione LR, **Rosenkranz SL**, Aweeka F, Coombs R, Zorrilla CD, Coughlin K, Moran L, Berzins B, Godfrey C, Cohn SE for the AIDS Clinical Trials Group A5316 Study Team. Intraindividual comparison of efavirenz, atazanavir, or ritonavir plasma pharmacokinetics before and during 21-days of vaginally administered hormone contraception. Accepted for oral presentation at the International Workshop on Clinical Pharmacology of Antiviral Therapy 2018, to be held 22-24 May 2018 in Baltimore, Maryland, USA.

#### **CONFERENCE PRESENTATIONS**

Scarsi KK, Cramer YS, Gingrich D, **Rosenkranz SL**, Aweeka F, Coombs R, Zorrilla CD, Coughlin K, Moran LE, Berzins B, Godfrey C, Cohn SE. Vaginal contraceptive hormone exposure profoundly altered by EFV- and ATV/r-based ART. Oral presentation at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, in Boston, MA, USA.

Lodise TP, **Rosenkranz SL**, Holland T, Finnemeyer M, Huvane J, Pereira C, Fowler V, Chambers H. The Emperor's New Clothes: Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE). Oral presentation at ID Week, October 4-8, 2017, in San Diego, CA, USA. Abstract 65435.

Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, **Rosenkranz SL**, Danziger LH, Rodvold KA. Phase I study to evaluate the pharmacokinetics of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants. Poster presentation at ID Week, October 4-8, 2017, in San Diego, CA, USA.

Bleasdale SC, Wenzler E, Sikka M, Bunnell KL, Finnemeyer M, **Rosenkranz SL**, Danziger LH, Rodvold KA. Phase I study to evaluate the safety and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants. Poster presentation at ID Week, October 4-8, 2017, in San Diego, CA, USA.

De Boni RB, Zheng L, **Rosenkranz SL**, Sun X, Cardoso SW, Grinsztejn B, La Rosa A, Pierre S, Collier AC, Gross R. Binge Drinking Decreases Weekend Adherence in an RCT from Low/Middle Income Countries. Presented at the IAPAC 10th International Conference on HIV Treatment and Prevention Adherence, Miami FL, June 28-30, 2015.

Kiser JJ, Lu D, **Rosenkranz SL**, Morse GD, Sherman KE, Butt A. Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons - AIDS Clinical Trials Group Study A5309s. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC. May 19-21, 2014. Poster number 18.

Gross R, Zheng L, La Rosa A, Sun X, **Rosenkranz S**, Cardoso-Wagner S, Ssali F, Camp R, Godfrey C, Collier AC for the ACTG A5234 Team. Partner-based Intervention for Adherence to Second-line ART: A Multinational RCT (ACTG A5234). Poster presentation, Conference on Retroviruses & Opportunistic Infections, Boston MA; March 3–6, 2014.

Guedj J, Ribeiro RM, Andrade A, **Rosenkranz SL**, Lu D, Richman D, Strain M, Mellors J, Kuritzkes D and Perelson AS for the ACTG A5249s protocol team. Analyses of HIV-1 viral dynamics during treatment with a regimen including an integrase inhibitor. Poster presentation, Conference on Retroviruses & Opportunistic Infections, Boston MA; March 3–6, 2014.

Luetkemeyer AF, **Rosenkranz SL**, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, and Haas DW, for ACTG A5221 and ACTG A5243 Study teams. Relationship between Efavirenz Troughs & CYP2B6 alleles with Rifampin-based TB Therapy in STRIDE. Poster presentation, Conference on Retroviruses & Opportunistic Infections, Boston MA; March 3–6, 2014.

**Rosenkranz S**. Invited Chair. Pharmacometrics Symposium: Modeling and Simulation in Drug Development. Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester NY. June 1, 2012.

Luetkemeyer AF, **Rosenkranz S**, Lu D, Lizak PS, Ive P, Swindells S, Benson C, Grinzstejn B, Sanne I, Havlir DV, Aweeka F, Adult AIDS Clinical Trials Group A5221 Team. Relationship between weight, efavirenz(EFV) concentrations and virologic suppression in HIV+ patients on rifampin (RIF)-based TB treatment in the ACTG 5221 STRIDE study. Session on Pharmacology of Old and New TB Drugs. Oral presentation at the XIX International AIDS Society conference, Washington DC, USA; July 22-27, 2012.

DiFrancesco R, **Rosenkranz SL**, Taylor CR, Pande P, Siminski SM, Jenny RW and Morse GD. Clinical Pharmacology Quality Assurance (CPQA) Program: Longitudinal Analysis of Antiretroviral (ARV) Proficiency Testing for International Laboratories. Poster presentation at the XIX International AIDS Society conference, Washington DC, USA; July 22-27, 2012. Abstract 13372.

**Rosenkranz S**. Invited discussant, themed poster discussion. Pharmacometrics: Drug Exposure and Response modeling. 19th Conference on Retroviruses & Opportunistic Infections, Boston MA; March 5–8, 2012.

Adriana A, **Rosenkranz S**, Cillo A, Lu D, Daar E, Feinberg J, Read S, Acosta E, Kuritzkes D and Mellors J for the ACTG 5248 Team. Three Phases of Plasma HIV-1 RNA Decay Revealed by Single Copy Assay (SCA) in Antiretroviral-Naïve Patients Initiating ART with Raltegravir (RAL), Tenofovir (TDF) and Emtricitabine (FTC) (ACTG A5248). Poster presentation, 19th Conference on Retroviruses & Opportunistic Infections, Boston MA; March 5–8, 2012.

DiFrancesco R, **Rosenkranz SL**, Siminski SM, Pande P, Taylor C, Tooley KM, Jenny RW, Morse GD. Proficiency testing program supports the accuracy of antiretroviral concentrations used in HIV clinical trials network. Poster presentation, 12<sup>th</sup> International Workshop on Clinical Pharmacology of HIV Therapy, April 10-13, 2011; Miami, FL, USA.

Andrade A, **Rosenkranz SL**, Lu D, Mellors J, Read S, Feinberg J, Flexner C, Acosta E, Lederman M, Kuritzkes D for the ACTG 5249s protocol team. ACTG 5249s: Time to Onset of First-Phase Viral Decay in Antiretroviral-Naïve Patients Treated with Raltegravir and Emtricitabine (FTC) /Tenofovir (TDF). Poster presentation, 18th Conference on Retroviruses & Opportunistic Infections, Boston MA; February 27 – March 2, 2011.

Funderburg NT, Andrade A, Chan ES, Lu D, **Rosenkranz SL**, Jacobson J, Mellors J, Daar E, Kuritzkes D and Lederman MM. Delayed Reduction in CD4 T Cell Turnover Following Viral Control Correlates with Markers of Microbial Translocation in Treatment-Naïve Patients Receiving Raltegravir (RAL)-based Antiretroviral Therapy (ART): Preliminary Results from ACTG A5248. Poster presentation, 18<sup>th</sup> Conference on Retroviruses & Opportunistic Infections; Boston MA; February 27- March 2, 2011.

Andrade A, **Rosenkranz SL**, Daar E, Jacobson J, Acosta E, Lederman M, Touw J, Campbell T, Mellors J and Kuritzkes D for the ACTG A5248 Study Team. Longer Phase I Viral Decay in Treatment-Naïve Patients Receiving Raltegravir (RAL)-based Antiretroviral Therapy (ART): Preliminary Results from ACTG A5248. Poster presentation, 17<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; February 8-11, 2010.

Asmuth D, **Rosenkranz S**, Cramer Y, Lertora J, Rinaldo C, Murphy R, Schooley R, Thielman N, Li X-D, Pollard R, and ACTG A5192. Pharmacokinetic and Pharmacodynamic Parameters in HIV-1 Subjects Receiving Pegylated Interferon-alfa-2a Therapy: AIDS Clinical Trials Group Study 5192. Oral Abstract, 16<sup>th</sup> Conference on Retroviruses & Opportunistic Infections, Montreal, Canada; February 8-11, 2009.

Saag M, **Rosenkranz S**, Becker S, Klingman K, Kallungal B, Zadzilka A, Coakley E, Acosta E, Calandra G, Johnson V, and NIAID AIDS Clinical Trials Group, Bethesda, MD USA. Proof of Concept of Antiretroviral Activity of AMD11070 (an Orally Administered CXCR4 Entry Inhibitor): Results of the First Dosing Cohort A Studied in ACTG Protocol A5210. Poster Presentation, 14th Conference on Retroviruses & Opportunistic Infections, Los Angeles CA; February 25–28, 2007.

Gupta S, **Rosenkranz S**, Segal Y, Koletar S, Basar M, Szczech, Amorosa V, Hall S, and the AIDS Clinical Trials Group 5177 Protocol Team. The Steady State Pharmacokinetics of Efavirenz and Lopinavir/Ritonavir in HIV-Infected Persons Requiring Hemodialysis: AIDS Clinical Trials Group Study A5177. Poster Presentation, 13<sup>th</sup> Conference on Retroviruses & Opportunistic Infections, Denver CO; February 5–8, 2006.

**Rosenkranz S**, Yarasheski K, Para M, Reichman R, Morse G and the ACTG A5043 Team. Lipid, lipoprotein and gluco-regulatory changes during short-term protease inhibitor and efavirenz exposure in HIV-seronegative subjects: Results from ACTG A5043. Poster presentation #846. Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 24, 2005.

Ma Q, Forrest A, Okusanya OO, **Rosenkranz S**, Para MF, Yarasheski KE, Reichman RC, Morse GD and the AACTG A5043 Protocol Team. Pharmacokinetic (PK) Interaction Studies of Efavirenz (EFV) and Protease Inhibitors (PI) in HIV-Seronegative Volunteers. Poster presentation, Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, October 30 to November 4, 2004.

Ma Q, Forrest A, **Rosenkranz S**, Para MF, Adams E, Yarasheski K, Reichman RC, Morse GD, AACTG A5043 Protocol Team. Optimal multi-drug PK sampling strategies for efavirenz and indinavir. Poster presented at the International Society of Anti-Infective Pharmacology. October 30 to November 2, 2004, Washington, DC.

Ma Q, Forrest A, Okusanya OO, **Rosenkranz S**, Para MF, Yarasheski KE, Reichman RC, Morse GD and the AACTG A5043 Protocol Team. Pharmacokinetic interaction studies of efavirenz and protease inhibitors in HIV-seronegative volunteers. Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. October 30 to November 4, 2004, Washington, DC.

Zack J, Forrest A, Ma Q, **Rosenkranz S**, Para MF, Adams E, Yarasheski K, Reichman RC, Morse GD, AACTG A5043 Protocol Team. Optimal sparse PK sampling strategies for multi-drug antiretroviral regimens. Poster presented at the International Society of Anti-Infective Pharmacology. October 30 to November 2, 2004. Washington, DC.

Morse GD, **Rosenkranz S**, Para MF, Adams E, Yarasheski KE, Reichman RC and the ACTG 5043 Protocol Team. Three-way pharmacokinetic interaction among amprenavir, efavirenz and a second protease inhibitor. Poster presented at the 11th CROI, February 2004, San Francisco, CA.

Gerber JG, Fichtenbaum CJ, **Rosenkranz SL**, Vega JM, Yang A, Alston B, Brobst SW, Segal Y and Aberg JA for the ACTG A5108 Team. Efavirenz is a Significant Inducer of Simvastatin and Atorvastatin Metabolism: Results of ACTG 5108 Study. Poster Presentation, 11<sup>th</sup> Conference on Retroviruses & Opportunistic Infections, San Francisco CA; February 8-11, 2004.

Gerber JG, **Rosenkranz S**, Fichtenbaum CJ, Alston B, Brobst SW, Segal Y, and Aberg JA for the ACTG A5108 team. The Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Pravastatin. Poster Presentation, 2<sup>nd</sup> International AIDS Society Conference, Paris France; July 12-16, 2003.

Perlman DC, Remmel R, Brundage R, Owens S, Jones B, Horsburgh C, MacGregor RR, **Rosenkranz S**, Salomon N, Peloquin C. Rainey P, Hafner R for the ACTG 309 Protocol Team. Pharmacokinetics of antituberculous agents in persons with HIV-related tuberculosis. Presented at the 1999 Infectious Diseases Society Meeting, Philadelphia, PA 11/18-11/21/99.

**Rosenkranz SL**, Krupat E, Yeager CM, Barnard K. Doctor-Patient Fit and its Relationship to Patient Satisfaction. 1998 Joint Statistical Meetings. Dallas, TX, August 12, 1998.

**Rosenkranz SL**. Session Discussant for "Statistical Tools for Studying Health Care Costs: What Works and Where Do We Need Improvement." 1998 Joint Statistical Meetings. Dallas, TX, August 11, 1998.

**Rosenkranz SL**, Govoni LA, Oddliefson S, McGuirk SP, Lee P. Measuring Patient Satisfaction with Individual Clinicians. 1995 International Conference on Health Policy Research: Methodological Issues in Health Services and Outcomes Research. Boston, MA, December 2, 1995.

**Rosenkranz SL**. Fitting a Hierarchical Model to Count Data Using Gibbs Sampling. Invited Tutorial Session, Western North American Region of the International Biometric Society, June 26, 1995.

**Rosenkranz SL**. Approximate Bayes Factors for Outlier Identification: A Health Policy Application. Abstract and poster. Bayesian Statistics in Science and Technology: Case Studies Workshop. Carnegie-Mellon University, Pittsburgh, PA, October 1993.

Luft HS, **Rosenkranz SL**. Changing the focus: Applying Subscriber-Level Expenditure Models to Risk-Stratified Groups of Enrollees. Abstract and oral presentation. Association for Health Services Research Annual Meeting, Methods Workshop. San Diego, CA, June 29, 1993.

**Rosenkranz S**. What is Small Area Analysis, and how has it been used? Abstract and oral presentation. American Public Health Association Annual Meeting. New York City, NY, October 1990.